The eLitMed.hu medical portal uses computer cookies for convenient operation. Detailed information can be found in the Cookie-policy.
Hypertension and nephrology - 2018;22(03)
Content
Hypertension and nephrology
JUNE 10, 2018
Hypertension and nephrology
JUNE 10, 2018
Hypertension and nephrology
JUNE 10, 2018
Hypertension and nephrology
JUNE 10, 2018
Hypertension and nephrology
JUNE 10, 2018
Hypertension and nephrology
JUNE 10, 2018
Hypertension and nephrology
JUNE 10, 2018
[Antihypertensive effect of rilmenidine focusing on the Hungarian multicenter trial VERITAS]
[Summary in the antihypertensive therapy, in addition to the RAS-blockers (ACE-inhibitors or ARBs), calcium antagonists and thizid-like diuretics, other antihypertensive drugs with different mechanisms of actions, such as the imidazoline I1 receptor agonists, are beneficially used. Several international and Hungarian studies showed the results of the effects of these agents. Authors emphasize the effects of the VERITAS study showing that in hypertensive patients the imidazoline I1 receptor agonist, rilmenidine significantly decreased the office blood pressure as well as the blood pressure measured by ambulatory blood pressure monitoring (ABPM). The white-coat reaction and left ventricular hypertrophy (LVH) were also decreased. In a separate study involving hypertensive subjects rilmenidine significantly increased baroreflex sensitivity. This effect may contribute - mainly during daytime - to the antihypertensive effect. Authors summarise the most important actions of rilmenidine, and the selected publications on the results of the Hungarian and international investigations.]
Hypertension and nephrology
JUNE 10, 2018
Hypertension and nephrology
JUNE 10, 2018
Hypertension and nephrology
JUNE 10, 2018
Hypertension and nephrology
JUNE 10, 2018
1.
2.
Clinical Neuroscience
Alexithymia is associated with cognitive impairment in patients with Parkinson’s disease
08. JUN
3.
4.
5.
1.
2.
3.
4.
5.